351 related articles for article (PubMed ID: 18628403)
41. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.
Bubser M; Bridges TM; Dencker D; Gould RW; Grannan M; Noetzel MJ; Lamsal A; Niswender CM; Daniels JS; Poslusney MS; Melancon BJ; Tarr JC; Byers FW; Wess J; Duggan ME; Dunlop J; Wood MW; Brandon NJ; Wood MR; Lindsley CW; Conn PJ; Jones CK
ACS Chem Neurosci; 2014 Oct; 5(10):920-42. PubMed ID: 25137629
[TBL] [Abstract][Full Text] [Related]
42. Role of Conserved Tyrosine Lid Residues in the Activation of the M
Pham V; Habben Jansen MCC; Thompson G; Heitman LH; Christopoulos A; Thal DM; Valant C
Mol Pharmacol; 2023 Sep; 104(3):92-104. PubMed ID: 37348914
[TBL] [Abstract][Full Text] [Related]
43. New insight into active muscarinic receptors with the novel radioagonist [³H]iperoxo.
Schrage R; Holze J; Klöckner J; Balkow A; Klause AS; Schmitz AL; De Amici M; Kostenis E; Tränkle C; Holzgrabe U; Mohr K
Biochem Pharmacol; 2014 Aug; 90(3):307-19. PubMed ID: 24863257
[TBL] [Abstract][Full Text] [Related]
44. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats.
Brady AE; Jones CK; Bridges TM; Kennedy JP; Thompson AD; Heiman JU; Breininger ML; Gentry PR; Yin H; Jadhav SB; Shirey JK; Conn PJ; Lindsley CW
J Pharmacol Exp Ther; 2008 Dec; 327(3):941-53. PubMed ID: 18772318
[TBL] [Abstract][Full Text] [Related]
45. The role of membrane proximal threonine residues conserved among guanine-nucleotide-binding-protein-coupled receptors in internalization of the m4 muscarinic acetylcholine receptor.
Van Koppen CJ; Lenz W; Nunes JP; Zhang C; Schmidt M; Jakobs KH
Eur J Biochem; 1995 Dec; 234(2):536-41. PubMed ID: 8536700
[TBL] [Abstract][Full Text] [Related]
46. Importance of receptor expression in the classification of novel ligands at the M
Jiang Y; Yeasmin M; Gondin AB; Christopoulos A; Valant C; Burger WAC; Thal DM
Br J Pharmacol; 2024 Jul; 181(14):2338-2350. PubMed ID: 36550621
[TBL] [Abstract][Full Text] [Related]
47. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100.
Byun NE; Grannan M; Bubser M; Barry RL; Thompson A; Rosanelli J; Gowrishankar R; Kelm ND; Damon S; Bridges TM; Melancon BJ; Tarr JC; Brogan JT; Avison MJ; Deutch AY; Wess J; Wood MR; Lindsley CW; Gore JC; Conn PJ; Jones CK
Neuropsychopharmacology; 2014 Jun; 39(7):1578-93. PubMed ID: 24442096
[TBL] [Abstract][Full Text] [Related]
48. Structure-Activity Relationships of Pan-Gα
Berizzi AE; Bender AM; Lindsley CW; Conn PJ; Sexton PM; Langmead CJ; Christopoulos A
ACS Chem Neurosci; 2018 Jul; 9(7):1818-1828. PubMed ID: 29683647
[TBL] [Abstract][Full Text] [Related]
49. Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors.
Jakubík J; Bacáková L; el-Fakahany EE; Tucek S
J Pharmacol Exp Ther; 1995 Sep; 274(3):1077-83. PubMed ID: 7562472
[TBL] [Abstract][Full Text] [Related]
50. Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies.
Lazareno S; Gharagozloo P; Kuonen D; Popham A; Birdsall NJ
Mol Pharmacol; 1998 Mar; 53(3):573-89. PubMed ID: 9495826
[TBL] [Abstract][Full Text] [Related]
51. State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.
Gould RW; Nedelcovych MT; Gong X; Tsai E; Bubser M; Bridges TM; Wood MR; Duggan ME; Brandon NJ; Dunlop J; Wood MW; Ivarsson M; Noetzel MJ; Daniels JS; Niswender CM; Lindsley CW; Conn PJ; Jones CK
Neuropharmacology; 2016 Mar; 102():244-53. PubMed ID: 26617071
[TBL] [Abstract][Full Text] [Related]
52. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
Olianas MC; Maullu C; Onali P
Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494
[TBL] [Abstract][Full Text] [Related]
53. Structural Features of Iperoxo-BQCA Muscarinic Acetylcholine Receptor Hybrid Ligands Determining Subtype Selectivity and Efficacy.
Wakeham MCL; Davie BJ; Chalmers DK; Christopoulos A; Capuano B; Valant C; Scammells PJ
ACS Chem Neurosci; 2022 Jan; 13(1):97-111. PubMed ID: 34905693
[TBL] [Abstract][Full Text] [Related]
54. A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation.
Canals M; Lane JR; Wen A; Scammells PJ; Sexton PM; Christopoulos A
J Biol Chem; 2012 Jan; 287(1):650-659. PubMed ID: 22086918
[TBL] [Abstract][Full Text] [Related]
55. Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice.
Traut J; Mengual JP; Meijer EJ; McKillop LE; Alfonsa H; Hoerder-Suabedissen A; Song SH; Fehér KD; Riemann D; Molnar Z; Akerman CJ; Vyazovskiy VV; Krone LB
Elife; 2023 Mar; 12():. PubMed ID: 36892930
[TBL] [Abstract][Full Text] [Related]
56. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
[TBL] [Abstract][Full Text] [Related]
57. Characterization of the subtype selectivity of the allosteric modulator heptane-1,7-bis-(dimethyl-3'-phthalimidopropyl) ammonium bromide (C7/3-phth) at cloned muscarinic acetylcholine receptors.
Christopoulos A; Sorman JL; Mitchelson F; El-Fakahany EE
Biochem Pharmacol; 1999 Jan; 57(2):171-9. PubMed ID: 9890565
[TBL] [Abstract][Full Text] [Related]
58. Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.
MacLaren DA; Browne RW; Shaw JK; Krishnan Radhakrishnan S; Khare P; España RA; Clark SD
eNeuro; 2016; 3(5):. PubMed ID: 27822508
[TBL] [Abstract][Full Text] [Related]
59. Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or Compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?
Tran FH; Spears SL; Ahn KJ; Eisch AJ; Yun S
Neurosci Lett; 2020 Nov; 739():135432. PubMed ID: 33080350
[TBL] [Abstract][Full Text] [Related]
60. Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M
van der Westhuizen ET; Spathis A; Khajehali E; Jörg M; Mistry SN; Capuano B; Tobin AB; Sexton PM; Scammells PJ; Valant C; Christopoulos A
Mol Pharmacol; 2018 Jul; 94(1):770-783. PubMed ID: 29691279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
